self-amplifying RNA cancer vaccine / Boehringer Ingelheim, University of California - LARVOL DELTA

Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov) - P1/2; N=56; Active, not recruiting; Sponsor: Ludwig Institute for Cancer Research; Recruiting ➔ Active, not recruiting; Trial primary completion date: Mar 2021 ➔ Oct 2021

Clinical • Enrollment closed • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor